APPENDICES - NIHR Health Technology Assessment Programme

More documents

Recommendations

Info

148 Appendix 6 carcinomas: 5 years experience.] Nederland Tijdschr Dermatol Venereol 2004;14:307–13. 196. Thompson MS, Andersson-Engels S, Svanberg S, Johansson T, Palsson S, Bendsoe N, et al. Photodynamic therapy of nodular basal cell carcinoma with multifiber contact light delivery. J Environ Pathol Tox 2006;25:411–24. 197. Tindholdt TT, Tonseth KA, Bjaerke TK, Abyholm FE. [Photodynamic therapy of facial basal cell carcinoma.] Tidsskr Nor Laegeforen 2007;127: 1928–30. 198. Tobola J, Witkowska A, Ostrowski J, Kucharczyk Z. [Topical treatment of superficial basal cell carcinomas with 5% 5-fluorouracil ointment.] Przegl Dermatol 2003;90:357–62. 199. Toll A, Parera Ma E, Velez M, Pujol RM. Photodynamic therapy with methyl aminolevulinate induces phototoxic reactions on areas of the nose adjacent to basal cell carcinomas and actinic keratoses. Dermatol Surg 2008;34:1145–7. 200. Toll A, Parera ME, Velez M, Pujol RM. Letter: photodynamic therapy with methyl aminolevulinate induces phototoxic reactions on areas of the nose adjacent to basal cell carcinomas and actinic keratoses. Dermatol Surg 2008;34:1145–7; discussion 7–8. 201. Tomio L, Corti L, Polico C, Maluta S, Calzavara F, Norberto L, et al. [Laser-photo-radiotherapy in the treatment malignant tumors.] Radiol Med 1987;73:313–16. 202. Tope WD, Ross EV, Kollias N, Martin A, Gillies R, Anderson RR. Protoporphyrin IX fluorescence induced in basal cell carcinoma by oral delta-aminolevulinic acid. Photochem Photobiol 1998;67:249–55. 203. Tosca AD, Balas CJ, Stefanidou MP, Katsantonis JC, Georgiou S, Tzardi MN, et al. Prediction of ALA-PDT efficacy through remote color inspection and post therapy sequential histologic observations of skin malignancies. SPIE Proceedings Series 1997;3191:221–30. 204. Tse DT, Kersten RC, Anderson RL. Hematoporphyrin derivative photoradiation therapy in managing nevoid basal-cell carcinoma syndrome. A preliminary report. Arch Ophthalmol 1984;102:990–4. 205. Umegaki N, Moritsugu R, Katoh S, Harada K, Nakano H, Tamai K, et al. Photodynamic therapy may be useful in debulking cutaneous lymphoma prior to radiotherapy. Clin Exp Dermatol 2004;29:42–5. 206. Usmani N, Telfer NR, Stables GI. Subungual Bowen’s disease treated by topical photodynamic therapy. Br J Dermatol 2004;151:96. 207. Vaicova M, Ettler K. [Our clinical experience with the use of photodynamic therapy in patients with the basal cell carcinoma and morbus Bowen (comparison of efficacy of two photosensitizers).] Cesk Dermatol 2004;79:200–4. 208. Vakoulovskaia E, Chental V, Kuvshinov Y, Poddubny B, Ivanov AV, Kazaryan MA. New approaches to photodynamic therapy of tumors with Al phthalocyanine. SPIE Proceedings Series 2000;4059:32–8. 209. Vakulovskaya EG, Kemov YV, Zalevsky ID, Reshetnikov AV, Umnova LV, Vorozhcsov GN. Photodynamic therapy and fluorescent diagnostics of skin cancer with radochlorine and photosense, comparing efficacy and toxicity. SPIE Proceedings Series 2004;5315:148–51. 210. Van de Mierop F, Lightdale CJ. Use of atropine during endoscopy: benefit during photodynamic therapy. Gastrointest Endosc 1996;44:512. 211. Van Oosten EJ, Kuijpers DIM, Thissen MRTM. Different pain sensations in photodynamic therapy of nodular basal cell carcinoma: results from a prospective trial and a review of the literature. Photodiag Photodyn Ther 2006;3:61–8. 212. Varma S, Anstey A, Wilson H, Kurwa HA. Photodynamic therapy for the treatment of Bowen’s disease, solar keratoses, and superficial basal cell carcinomas: 12 months experience with a novel light source. Br J Dermatol 1998;139:19. 213. Varma S, Wilson H, Kurwa HA, Charman C. One year relapse rates for Bowen’s disease, basal cell carcinomas and solar keratoses treated by photodynamic therapy: analysis of 189 lesions. Br J Dermatol 1999;141:114–18. 214. Varma S, Wilson H, Kurwa HA, Gambles B, Charman C, Pearse AD, et al. Bowen’s disease, solar keratoses and superficial basal cell carcinomas treated by photodynamic therapy using a largefield incoherent light source. Br J Dermatol 2001;144:567–74. 215. Vinciullo C, Elliott T, Francis D. MAL-PDT in “difficult-to-treat” basal cell carcinoma, an Australian study: 48 month follow-up data. J Invest Dermatol 2006;126:S34. 216. Vinciullo C, Elliott T, Francis D, Gebauer K, Spelman L, Nguyen R, et al. Photodynamic therapy with topical methyl aminolaevulinate for ‘difficult-to-treat’ basal cell carcinoma. Br J Dermatol 2005;152:765–72.
DOI: 10.3310/hta14370 Health Technology Assessment 2010; Vol. 14: No. 37 217. Viniciullo C, Elliott T, Gebauer K, Spelman L. Photodynamic therapy using methyl aminolevulinate in patients with basal cell carcinoma. J Am Acad Dermatol 2004;50:P478. 218. Waldow SM, Lobraico RV, Kohler IK, Wallk S, Fritts HT. Photodynamic therapy for treatment of malignant cutaneous lesions. Lasers Surg Med 1987;7:451–6. 219. Wang J, Gao M, Wen S, Wang M. Photodynamic therapy for 50 patients with skin cancers or precancerous lesions. Chin Med Sci J 1991;6:163–5. 220. Wang JB, Gao ML, Wen SJ, Wang MJ. Study of photodynamic therapy in skin cancers and precancerous lesions. SPIE Proceedings Series 1993;1616:139–42. 221. Wang XL, Wang HW, Guo MX, Xu SZ. Treatment of skin cancer and pre-cancer using topical ALA-PDT: a single hospital experience. Photodiag Photodyn Ther 2008;5:127–33. 222. Warloe T, Peng Q, Heyerdahl H, Moan J, Steen HB, Giercksky KE. Photodynamic therapy with 5-aminolevulinic acid induced porphyrins and DMSO/EDTA for basal cell carcinoma. SPIE Proceedings Series 1995;2371:226–35. 223. Weisser H, Meyer-Rogge D, Meyer-Rogge E. [First experiences in medical practice with the new topical photosensitizer MAOP for actinic keratosis and basal cell carcinoma.] Aktuelle Dermatol 2004;30:306–11. 224. Wennberg AM, Lindholm LE, Alpsten M, Larko O. Treatment of superficial basal cell carcinomas using topically applied delta-aminolaevulinic acid and a filtered xenon lamp. Arch Dermatol Res 1996;288:561–4. 225. Whitaker IS, Shokrollahi K, James W, Mishra A, Lohana P, Murison MC. Combined CO(2) laser with photodynamic therapy for the treatment of nodular basal cell carcinomas. Ann Plast Surg 2007;59:484–8. 226. Wilson BD, Mang TS, Cooper M, Stoll H. Use of photodynamic therapy for the treatment of extensive basal cell carcinomas. Facial Plast Surg 1989;6:185–9. © 2010 Queen’s Printer and Controller of HMSO. All rights reserved. 227. Wilson BD, Mang TS, Stoll H, Jones C, Cooper M, Dougherty TJ. Photodynamic therapy for the treatment of basal cell carcinoma. Arch Dermatol 1992;128:1597–601. 228. Wolf P, Fink-Puches R, Reimann-Weber A, Kerl H. Development of malignant melanoma after repeated topical photodynamic therapy with 5-aminolevulinic acid at the exposed site. Dermatology 1997;194:53–4. 229. Wolf P, Rhodes L, Fritsch C. MAL-PDT in the treatment of difficult-to-treat basal cell carcinoma: 36-month update. J Am Acad Dermatol 2005;52:P162. 230. Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? [Erratum published in J Am Acad Dermatol 1993;29:41.] J Am Acad Dermatol 1993;28:17–21. 231. Xu S, Wang X, Xu W. [Evaluation of photodynamic therapy of skin cancers with delta-aminolevulinic acid.] Med J Wuhan Univ 2003;24:86–9. 232. Xu S, Wang X, Xu W, Xia Y, Zhang C. Evaluation of photodynamic therapy of skin cancers with partial differential alpha-aminolevulinic acid. Chin Med J 2002;115:1141–5. 233. Yokoyama S, Nakano H, Nishizawa A, Kaneko T, Harada K, Hanada K. A case of photocontact urticaria induced by photodynamic therapy with topical 5-aminolaevulinic acid. J Dermatol 2005;32:843–7. 234. Zane C, Venturini M, Sala R, Calzavara-Pinton P. Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T-cell lymphoma. Photodermatol Photoimmunol Photomed 2006;22:254–8. 235. Zeng CY, Yang D, Wang KH, Cao QQ. Interstitial photodynamic therapy for cancers of cavum oris, skin and cervix. SPIE Proceedings Series 1993;1616:102–7. 149
Page 1 and 2: Appendices July 2010 10.3310/hta143
Page 3 and 4: DOI: 10.3310/hta14370 Health Techno
Page 9: DOI: 10.3310/hta14370 Health Techno
Page 12 and 13: 140 Appendix 6 18. Biel MA. Photody
Page 14 and 15: 142 Appendix 6 63. Gonzalez-Perez R
Page 16 and 17: 144 Appendix 6 treated with photody
Page 18 and 19: 146 Appendix 6 aminolevulinic acid
Page 38 and 39: 166 Appendix 9 photodynamic therapy
Page 40 and 41: 168 Appendix 9 of early-stage lung
Page 42 and 43: 170 Appendix 9 107. Okunaka T, Kato
Page 44 and 45: 172 Appendix 9 152. Kato H, Konaka
Page 54 and 55: 182 Appendix 12 as salvage treatmen
Page 56 and 57: 184 Appendix 12 63. Lorenz KJ, Maie
Page 58 and 59: 186 Appendix 12 107. Biel MA. Photo
Page 60 and 61: 188 Appendix 13 Study details Popul
Page 70 and 71:
198 Appendix 13 Study details Popul
Page 72 and 73:
Page 74 and 75:
Page 76 and 77:
Page 78 and 79:
Page 80 and 81:
Page 82 and 83:
Page 84 and 85:
Page 86 and 87:
Appendix 13 214 Study details Popul
Page 89 and 90:
DOI: 10.3310/hta14370 Health Techno
Page 91 and 92:
Page 93 and 94:
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138:
Page 139 and 140:
Page 141 and 142:
Page 143 and 144:
Study details Population details Tr
Page 145 and 146:
Page 147 and 148:
Page 149 and 150:
Page 151 and 152:
Page 153:
Page 156 and 157:
Page 158 and 159:
Appendix 21 286 Study details Popul
Page 162:
Feedback The HTA programme and the
show all

APPENDICES - NIHR Health Technology Assessment Programme

Create successful ePaper yourself

Delete template?

Save as template?